Stockscreener 앱 받기
151.56
1.41%
-2.17
Revolution Medicines Inc 주식(RVMD)의 최신 뉴스
Total equity of Revolution Medicines, Inc. – BMV:RVMD - TradingView
Price to earnings ratio of Revolution Medicines, Inc. – BMV:RVMD - TradingView
Revolution Medicines, Inc. Balance Sheet – BMV:RVMD - TradingView
Revolution Medicines stock hits all-time high at 155.72 USD By Investing.com - Investing.com Nigeria
RVMD Initiated Coverage by BernsteinPrice Target Announced at $151 - GuruFocus
Revolution Medicines stock hits all-time high at 155.72 USD - Investing.com
Bernstein Initiates Revolution Medicines at Market Perform - Moomoo
Revolution Medicines to host webcast on phase 3 trial results By Investing.com - Investing.com Australia
RVMD reports wider-than-expected loss in Q1, raises '26 expense view - MSN
Revolution Medicines to host webcast on phase 3 trial results - Investing.com UK
Bernstein initiates Revolution stock coverage at Market Perform on valuation - Investing.com UK
Revolution Medicines (RVMD) Coverage Initiated with Market Perfo - GuruFocus
Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation - The Manila Times
Pancreatic cancer trial results prompt May 31 Revolution Medicines call - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Eagle Health Investments LP Makes New $9.23 Million Investment in Revolution Medicines, Inc. $RVMD - MarketBeat
Is Daraxonrasib’s Phase 3 Pancreatic Cancer Data And EQRx Deal Altering The Investment Case For Revolution Medicines (RVMD)? - Yahoo Finance
Revolution Medicines Recasts RAS Story With Phase 3 Win And New Firepower - simplywall.st
Profund Advisors LLC Has $2.15 Million Stock Holdings in Revolution Medicines, Inc. $RVMD - MarketBeat
Needham Keeps Buy Rating on Revolution Medicines (RVMD) Despite Wider Loss - Insider Monkey
ERASCA INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Erasca, Inc. on Behalf of Erasca Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Revolution Medicines, Inc.Common Stock (NQ: RVMD - FinancialContent
Truist assumes Revolution stock coverage with buy on cancer drug potential - Investing.com
Revolution Medicines, Inc. (RVMD) Stock Analysis: Biotech Heavyweight with 24% Potential Upside - DirectorsTalk Interviews
JP Morgan Maintains Revolution Medicines (RVMD) Overweight Recommendation - MSN
Assessing Revolution Medicines (RVMD) Valuation After A Powerful Multi Year Shareholder Return Run - Yahoo Finance
Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report - Sahm
Janus Henderson Group reports stake in Revolution Medicines (RVMD) — 9.77M shares - Stock Titan
Why (RVMD) Price Action Is Critical for Tactical Trading - Stock Traders Daily
AIHC Capital Management Ltd Acquires New Holdings in Revolution Medicines, Inc. $RVMD - MarketBeat
Piper Sandler Initiates Coverage of Revolution Medicines (RVMD) with Overweight Recommendation - MSN
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug - Reuters
Revolution Medicines (RVMD) down 8.8% since last earnings report: Can it rebound? - MSN
Revolution Medicines Advances Daraxonrasib Into Phase 3 Pancreatic Cancer Trial, Raising Long-Term Upside Potential - TipRanks
RVMD Stock Price, Quote & Chart | REVOLUTION MEDICINES INC (NASDAQ:RVMD) - ChartMill
Revolution Medicines Warrants: Balancing Dilution Risk and Potential Worthlessness Ahead of 2026 Expiry - TipRanks
How an ‘Impossible’ Idea Led to a Pancreatic Cancer Breakthrough - The New York Times
Revolution Medicines outlines $1.7B-$1.8B in 2026 GAAP operating expenses while expanding RASolve 301 to 590 patients - MSN
Q2 EPS Forecast for Revolution Medicines Lowered by Analyst - MarketBeat
Revolution Medicines (RVMD) Receives FDA’s “Safe to Proceed” Letter for Daraxonrasib - Insider Monkey
Is It Too Late To Consider Revolution Medicines (RVMD) After A 240% One Year Surge? - Yahoo Finance
LifeSci Capital Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $263 - Moomoo
Is It Too Late To Consider Revolution Medicines (RVMD) After Its Recent Surge In Price? - simplywall.st
Should RVMD’s Wider Losses and Daraxonrasib Progress Require Action From Revolution Medicines (RVMD) Investors? - simplywall.st
10 Best Performing Healthcare Stocks So Far in 2026 - Insider Monkey
First RAS Inhibitor Extends Survival in Previously Treated Metastatic Pancreatic Adenocarcinoma: What You Need to Know - Pancreatic Cancer Action Network
0.20%
1.02%
자본화:
|
볼륨(24시간):